Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody study
Two new Regeneron studies appeared this week, one recruiting for allergic conjunctivitis and one not yet enrolling for eye pressure disorders.
Regeneron posted two new trial registrations this week covering eye conditions.
- A Phase 3 study (NCT07675811) is recruiting to test two experimental medicines, freneslerbart and mevonlerbart, which when given together are called REGN-2Cat1, in adult and pediatric patients with allergic conjunctivitis due to cat allergy. The trial's primary outcome is ocular itch score in participants receiving REGN-2Cat as compared to placebo1, with enrollment estimated at 570 participants.
- A Phase 1/2 study (NCT07675824), acronym BAHAMA, is not yet recruiting to test REGN22530 in participants with primary open angle glaucoma or ocular hypertension2. The drug is designed to bind a protein in the eye linked to fluid buildup and increased intraocular pressure, blocking it so more fluid can drain and pressure can decrease2, with enrollment estimated at 271 participants.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.